SVD-1a

SVD-1a is an all-D-enantiomeric peptide ligand designed to target and disassemble alpha-synuclein (α-syn) aggregates, which are central to the pathogenesis of Parkinson's disease and other synucleinopathies. Developed by researchers at Forschungszentrum Jülich and Heinrich Heine University Düsseldorf, SVD-1a was identified through mirror-image phage display and next-generation sequencing. It exhibits high affinity for α-syn in the picomolar range and acts by destabilizing toxic oligomeric assemblies, converting them back into physiological monomers. In preclinical studies, SVD-1a has demonstrated the ability to reduce toxic effects and intracellular seeding capacity of preformed α-syn oligomers in cell culture, suggesting potential as a disease-modifying treatment.